The risk predictive values of UK‐PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti‐gp210
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary: Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK‐PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK‐PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti‐gp210 as a biomarker, and to investigate whether anti‐gp210 could affect the prognostic values of UK‐PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti‐gp210+ and 143 anti‐gp210− patients. Results: The 5‐year adverse outcome‐free survivals of anti‐gp210+ vs. anti‐gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 10 9 (P < 0.001) had a superimposition effect on anti‐gp210 antibody as a risk factor. Furthermore, long‐term prognoses were evaluated using the UK‐PBC and GLOBE scores. For UK‐PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti‐gp210+ patients (n = 110) and 0.888 for anti‐gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti‐gp210+ patients (n = 110) and 0.848 for anti‐gp210− patients (n = 113). UK‐PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK‐PBC and GLOBE scoring systems were good 5‐year prognostic predictors in Chinese patients with PBC, especially in anti‐gp210+ patients. As a biomarker, anti‐gp210 antibody was associated with a more severe cholestatic manifestation and a worse long‐term prognosis. The anti‐gp210 antibody could be added to further optimise the UK‐PBC and GLOBE scoring systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Self-citationLindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis
Muratori, P., Muratori, L., Ferrari, R., Cassani, F., Bianchi, G., Lenzi, M., Rodrigo, L., Linares, A., Fuentes, D., & Bianchi, F. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07257.x · Cited by 204
Trivedi, P. J., Bruns, T., Cheung, A., Li, K.-K., Kittler, C., Kumagi, T., Shah, H., Corbett, C., Al-Harthy, N., Acarsu, U., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.029 · Cited by 132
Zhang, L.-N., Shi, T.-Y., Shi, X.-H., Wang, L., Yang, Y.-J., Liu, B., Gao, L.-X., Shuai, Z.-W., Kong, F., Chen, H., et al. (2013) · Hepatology · doi:10.1002/hep.26322 · Cited by 113
Self-citationUsing GWAS to identify genetic predisposition in hepatic autoimmunity
Webb, G. J., & Hirschfield, G. M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.016 · Cited by 108
Yang, F., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Tang, R., Chen, X., Bian, Z., Zhang, H., Yang, Y., et al. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8516-5 · Cited by 71
Self-citationNakamura, M., Kondo, H., Tanaka, A., Komori, A., Ito, M., Yamamoto, K., Ohira, H., Zeniya, M., Hashimoto, E., Honda, M., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12423 · Cited by 49
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
“36 and to MELD and Child-Pugh scores [210-212] [213].”
BackgroundLleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Self-citationThe challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Self-citationHuang, C., Han, W., Wang, C., Liu, Y., Chen, Y., & Duan, Z. (2019) · Disease Markers · doi:10.1155/2019/9121207 · Cited by 32
“Three of the 5 studies compared the serum levels of ALT, ALP, TBIL, and IgM between the groups [14, 15, 17].”
BackgroundMethodInfluentialThe immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22
Metadata
- Authors
- Yang, F., Yang, Y., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Wei, Y., Bian, Z., Sheng, L., Chen, X., Qiu, D., Fang, J., Tang, R., Gershwin, M. E., & Ma, X.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-01-13
- Volume
- 45
- Issue
- 5
- Pages
- 733-743
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2575398213
- Cited by
- 89
- References
- 15
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.